While other animal models of RA have examined the role of IL-1, we chose to focus on TNF-α inhibition, as anti-IL-1 therapy has overall inferior clinical efficacy compared to TNF-α inhibitors in RA patients. This evidence concerns the gene TNF and rheumatoid arthritis.